Advanced Prostate Cancer COE

Genomic Analysis and Assessment of Treatment Patterns To Better Understand Disparities in Advanced Prostate Cancer – Brandon Mahal

Details
In this UroToday discussion Charles Ryan and Brandon Mahal, discuss Dr. Mahal’s recent update to his study that was published in last year’s New England Journal of Medicine. Dr. Mahal begins this conversation by discussing the background of his recent study, discussing the differences in mutational landscape, of advanced prostate cancer patients, between men with European and African ancestry. Dr....

Treatment Sequencing in Castrate-Resistant Metastatic Cancer - Mark Fleming

Details
In an educational session at the 2021 ASCO annual meeting titled Beyond the Androgen Receptor: New Avengers in the Treatment of Castrate-Resistant Metastatic Cancer, Mark Fleming, MD presented on treatment sequencing in castrate-resistant metastatic cancer (CRPC). In this conversation with Charles Ryan, MD, he speaks to the complex therapeutic landscape and offers guidance in managing treatment se...

Relugolix in the Treatment of Advanced Prostate Cancer- Neeraj Agarwal

Details
Neeraj Agarwal, MD joins Petros Grivas, MD, PhD, sharing his clinical perspective on using relugolix in patients with advanced prostate cancer, and how this new oral treatment option fits into the prostate cancer treatment algorithm. The phase 3 HERO trial looked at patients with advanced prostate cancer, locally advanced prostate cancer, as well as metastatic prostate cancer, and patients were ra...

Selection of Androgen Deprivation Therapy for Use in Advanced Prostate Cancer - Bertrand Tombal

Details
Joining Thomas Keane, MBBCh, FRCSI, FACS, diving into the data reported in the Phase III HERO trial is Bertrand Tombal, MD, PhD. In this conversation, Dr. Tombal drives awareness in the urology community on the use of oral relugolix and the benefits to patients. He discusses the clinical implications of the trial data, intermittent androgen deprivation therapy, the relevance of testosterone surge,...

Assessment and Treatment of Cardiovascular Risk Factors in Veterans with Prostate Cancer - Ravi Parikh and Lova Sun

Details
Cardiovascular disease is a leading cause of mortality in patients with prostate cancer, and androgen deprivation therapy (ADT) may worsen cardiovascular risk. Adherence to guideline-recommended assessment and management of cardiovascular risk factors (CVRFs) in patients initiating ADT is not understood. A recently published study that describes CVRF assessment and management in Veterans with pros...

Metastasis-Directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer A UroToday Journal Club - Christopher Wallis & Zachary Klaassen

Details
Christopher Wallis and Zachary Klaassen provide insights into the European Urology publication titled " Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis " in this UroToday Journal Club. The question that the authors sought to assess is if data could be derived assessing whether...

Advancing Knowledge About The Treatment of Advanced Prostate Cancer, Highlights from GU ASCO 2021 - Praful Ravi

Details
Praful Ravi, MB, BChir, MRCP, and Alicia Morgans, MD, MPH highlight several prostate cancer abstracts from GU ASCO 2021 and discuss the clinical landscape for treating prostate cancer. They highlight results of the ACIS trial assessing the combination of apalutamide + abiraterone acetate as compared to abiraterone acetate alone in patients with chemo-naive metastatic castration-resistant prostate...

Apalutamide Confirms Overall Survival Benefit at 44-Months in Metastatic Castration-Sensitive Prostate Cancer - The TITAN Study - Neeraj Agarwal

Details
In 2019 the first interim analysis of the phase III TITAN trial was reported which led to the approval of apalutamide for metastatic castration-sensitive prostate cancer (mCSPC). In this conversation with Alicia Morgans, MD, MPH, Neeraj Agarwal, MD highlights the final overall survival analysis after a median follow-up of 44 months (nearly 4-years) and the recent final survival analysis Journal of...

Patient Selection for ADT Treatment with the Oral GnRH Antagonist in Clinical Practice - Ashley Ross

Details
In this conversation Alicia Morgans, MD, MPH, and Ashley Ross, MD discuss his considerations of patient selection when using the oral GnRH antagonist, relugolix. Dr. Ross explains his thought process when considering oral ADT therapy for his patients, and outlines three specific scenarios when he leans into recommending its use for his patients and his approach to patient follow-up once oral treat...

Landscape of Circulating Tumor DNA Abnormalities in Advanced Prostate Cancer: Distinctions Between African-American and Caucasians - Pedro Barata

Details
In this conversation with Alicia Morgans, MD, MPH, Pedro Barata, MD, MSc, highlights two abstracts highlighting the importance of germline genetic testing in prostate cancer patients presented during the 2021 ASCO GU Cancers Symposium. Dr. Barata begins the abstract titled “ Landscape of Circulating Tumor DNA Abnormalities in Advanced Prostate Cancer: Distinctions Between African-American and Cauc...